Biopharmaceutical venture capital investment climbed from $4.52 billion in 2013 to $5.29 billion in 2014, a 17% increase, according to Dow Jones VentureSource.
Joel Marcus, chief executive of Alexandria Real Estate Equities Inc., has been in biotech since its early days. From 1984 to 1994, he had a law career with expertise in the biopharmaceutical industry that included time as general counsel and secretary of Kirin-Amgen Inc., a joint venture between Kirin Brewery Co. and Amgen Inc.